Treatment With Cyclooxygenase-2 Inhibitors Enables Repeated Administration of Vaccinia Virus for Control of Ovarian Cancer

This publication has 40 references indexed in Scilit:

• The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma
  Molecular Therapy, 2008
• Administration of Cyclooxygenase-2 Inhibitor Reduces Joint Inflammation but Exacerbates Osteopenia in IL-1α Transgenic Mice Due to GM-CSF Overproduction
  The Journal of Immunology, 2007
• Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: Inhibition of tumor angiogenesis with extensive tumor necrosis
  International Journal of Radiation Oncology*Biology*Physics, 2007
• Celecoxib Inhibits Cellular Growth, Decreases Ki-67 Expression and Modifies Apoptosis in Ovarian Cancer Cell Lines
  Archives of Medical Research, 2006
• Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine
  Clinical Cancer Research, 2006
• Radiosensitivity Enhancement by Celecoxib, a Cyclooxygenase (COX)-2 Selective Inhibitor, via COX-2–Dependent Cell Cycle Regulation on Human Cancer Cells Expressing Differential COX-2 Levels
  Cancer Research, 2005
• A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2–independent mechanism
  Blood, 2005
• Celecoxib activates a novel mitochondrial apoptosis signaling pathway
  The FASEB Journal, 2003
• In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of Cyclooxygenase-2 enzyme: mechanistic considerations
  International Journal of Radiation Oncology*Biology*Physics, 2002
• Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.
  Proceedings of the National Academy of Sciences, 1995